The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Chemosensitivity and endocrine sensitivity predicted by mammaprint and blueprint in the Neoadjuvant Breast Registry Symphony Trial (NBRST).
Pat W. Whitworth
No relevant relationships to disclose
Mark Gittleman
No relevant relationships to disclose
Stephanie Akbari
No relevant relationships to disclose
Lisette Stork
Employment or Leadership Position - Agendia
Femke De Snoo
Employment or Leadership Position - Agendia
Jessica Gibson
Employment or Leadership Position - Agendia
Peter D. Beitsch
No relevant relationships to disclose